Article info
PDFLetter
Letter to the editor re: Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment
- Correspondence to Dr Ronald L Koretz, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, USA; rkoretz{at}msn.com
Citation
Letter to the editor re: Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment
Publication history
- Accepted August 9, 2018
- First published August 31, 2018.
Online issue publication
November 21, 2018
Article Versions
- Previous version (21 November 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.